Currently licenced direct oral anticoagulants selectively target thrombin (eg, dabigatran) or
coagulation factor Xa (eg, apixaban, betrixaban, edoxaban, and rivaroxaban). Designed to …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Since its introduction in 1977, percutaneous coronary intervention has become one of the
most commonly performed therapeutic procedures worldwide. Such widespread diffusion …

Aims Rupture of the fibrous cap (RFC) and erosion of an intact fibrous cap (IFC) are the two
predominant mechanisms causing acute coronary syndromes (ACS). It is uncertain whether …

Objectives: The purpose of the study was to investigate the impact of oral anticoagulation
(OAC) type on clinical outcomes 1 year after transcatheter aortic valve replacement (TAVR) …

Coronary artery disease (CAD) continues to be the leading cause of mortality and morbidity
in developed countries. Assessment of pre-test probability (PTP) based on patient's …

Objectives To systematically review available evidence and establish guidelines related to
the risk of develo** thrombosis and the management of small animals with …

Aims Low-dose (LD) direct oral anticoagulants (DOACs) in adjunct to antiplatelet therapy,
known as dual-pathway inhibition (DPI), have been tested to prevent ischaemic events in …

Background There are limited contemporary data prevalence and outcomes of acute
ischemic stroke (AIS) complicating acute myocardial infarction (AMI). Methods and Results …

Objectives To systematically review available evidence to determine when small animals at
risk of thrombosis should be treated with antiplatelet agents and anticoagulants, which …